{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-001502","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2023-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.687819+00:00","generated_at":"2026-06-20T05:36:38.766623+00:00","sec_items":["3.03","5.03","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revelation Biosciences announces 1-for-35 reverse stock split effective Feb 1, 2023","bullets":["Reverse split reduces outstanding shares from ~23.5M to ~672,460 shares.","Authorized common stock increased from 100M to 500M shares via charter amendment.","Split intended to regain Nasdaq minimum bid compliance; new CUSIP 76135L 309.","Stockholders also ratified Baker Tilly US, LLP as auditor for FY 2023.","Proportionate adjustments applied to warrants, options, and equity awards."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-001502","json":"https://secwatch.observer/filing/0000950170-23-001502.json","markdown":"https://secwatch.observer/filing/0000950170-23-001502.md","text":"https://secwatch.observer/filing/0000950170-23-001502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023001502/0000950170-23-001502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023001502/revb-20230130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T05:36:38.766623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30fc30e00a3c866d51fb559321f1fff70cb2a3ef","claim":"REVELATION BIOSCIENCES, INC.: Amended certificate of incorporation to increase authorized common shares from 100,000,000 to 500,000,000 and effect a 1-for-35 reverse stock split (effective 2023-02-01).","evidence_excerpt":"On January 30, 2023, the Company filed a Certificate of Amendment of Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) reflecting the change in authorized shares of common stock from 100,000,000 to 500,000,000 and effecting a reverse stock split as of 12:01 a.m. Eastern Standard Time on February 1, 2023 with a ratio of 1-for-35","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023001502/0000950170-23-001502-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-02-01"}],"fact_type":"governance_change"},{"claim_id":"215cad3b49d9c4e37fedfb73e1111a7029e9f4b3","claim":"REVELATION BIOSCIENCES, INC. shareholders approved Reverse Stock Split at the 2023-01-30 meeting.","evidence_excerpt":"Proposal 2 – Reverse Stock Split Stockholders approved the board of directors to effect a Reverse Stock Split of the outstanding shares of our common stock within one (1) year of January 30, 2023, at a specific ratio within a range of one-for-twenty (1-for-20) to a maximum of a one-for-one hundred (1-for-100) split, with the specific ratio to be fixed within this range by the board of directors in its sole discretion without further stockholder approval, based on the votes listed below: For Against Abstain 56,353,405 3,599,118 3,125,315","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023001502/0000950170-23-001502-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-01-30"}],"fact_type":"shareholder_vote"},{"claim_id":"8f7f5073dbaa90e3ba4a8bf16bdeb82bdcd6d2f6","claim":"REVELATION BIOSCIENCES, INC. shareholders approved Ratification of the Auditor at the 2023-12-31 meeting.","evidence_excerpt":"Proposal 3 – Ratification of the Auditor Stockholders approved Baker Tilly US, LLP to audit our financial statements for the fiscal year ending December 31, 2023, based on the votes listed below: For Against Abstain 12,219,710 274,018 584,110","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023001502/0000950170-23-001502-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"da0ddc76ecfbed10e37db2334fe51a05dc086d2c","claim":"REVELATION BIOSCIENCES, INC. shareholders approved Increase in the Number of Shares of Authorized Common Stock.","evidence_excerpt":"Proposal 1 – Increase in the Number of Shares of Authorized Common Stock Stockholders approved the amendment to increase the number of authorized common stock from 100,000,000 to 500,000,000 shares, based on the votes listed below: For Against Abstain 53,329,345 6,506,571 3,241,922","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023001502/0000950170-23-001502-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}